Skip to content Skip to footer
Subscribe Now
Genmab and AbbVie
NEWS

AbbVie and Genmab Report Positive Data from the P-III Study of Epcoritamab Plus R-CHOP in Newly Diagnosed DLBCL

Shots: AbbVie and Genmab announced positive topline results from the P-III (EPCORE DLBCL-2) study, demonstrating a statistically significant and clinically meaningful improvement in PFS vs R-CHOP alone (SoC) in newly diagnosed diffuse large B-cell lymphoma (DLBCL) pts. with an IPI score of 2-5 The study evaluated fixed treatment duration epcoritamab(SC) plus rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and…
October 6, 2026

Read more

Roche
NEWS

Roche Reports the P-III (CELESTIMO) Trial Data on Lunsumio in Follicular Lymphoma

Shots: Roche has reported the P-III (CELESTIMO) trial assessing Lunsumio (mosunetuzumab) + lenalidomide vs MabThera + lenalidomide in pts with r/r follicular lymphoma who have received ≥1L of prior systemic therapy Trial met its 1EP, showing a statistically significant & clinically meaningful improvement in PFS, while OS data remained immature at the interim analysis; the…
September 17, 2026

Read more

NEWS

Genentech Reports the US FDA’s sBLA Acceptance of Lunsumio VELO + Polivy for R/R Large B-Cell Lymphoma

Shots: The US FDA has accepted sBLA for Genentech's Lunsumio VELO (mosunetuzumab-axgb; SC) + Polivy (polatuzumab vedotin-piiq) for treating adults with r/r LBCL, incl. diffuse large B-cell lymphoma (DLBCL), after ≥1L of systemic therapy (PDUFA: Feb 9, 2027) sBLA was backed by the P-III (SUNMO) study assessing Lunsumio VELO + Polivy (IV) vs R-GemOx in the above…
June 18, 2026

Read more

Abbvie
NEWS

AbbVie Reports Topline P-III (EPCORE DLBCL-1) Trial Data on Epcoritamab for R/R Diffuse Large B-cell Lymphoma (DLBCL)

Shots: AbbVie has reported topline P-III (EPCORE DLBCL-1) trial results assessing epcoritamab vs chemoimmunotherapy (R-GemOx or BR) in 483 adults with r/r DLBCL, who had received ≥1L of therapy (73% had received ≥2L) & were ineligible for HDT-ASCT Trial showed improved PFS, with improvements across CRR, DoR, & time to next treatment, plus the study did not…
January 19, 2026

Read more

VIEWPOINTS

Patient Characteristics Trends in CAR-T Therapies: Dr. Ira Zackon in a Stimulating Discussion with PharmaShots 

Shots:  In a retrospective study sourced from EHR data for DLBCL patients, groundbreaking insights were unearthed that could potentially shape the treatment landscape of CAR-T Therapies in DLBCL  Data from the 10-year study is divided into pre- and post-CAR-T eras to better reflect trends in patient demographics and disease progression  PharmaShots welcomes Dr. Ira Zackon,…
June 18, 2025

Read more

VIEWPOINTS

Standardizing DLBCL Treatment: Dr. John Burke in a Riveting Conversation with PharmaShots  

Shots:   In the five-year follow-up data from the randomized POLARIX study, where participants received R-CHOP with a placebo for polatuzumab (control arm) and Pola-R-CHP with a placebo for vincristine   The primary endpoint of the study was progression free survival, and the secondary endpoint was overall survival  PharmaShots welcomes Dr. John Burke from Rocky Mountain Cancer…
June 16, 2025

Read more

Load more